Iterum Therapeutics Plc (ITRM) - News Archive

Iterum Therapeutics Regains Full Nasdaq Compliance Amid Successful Rights OfferingIn an inspiring turn of events, Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company dedicated to developing n...

DUBLIN and CHICAGO, Aug. 06, 2024 - Iterum Therapeutics plc (Nasdaq: ITRM), a prominent clinical-stage pharmaceutical company specializing in the development of next-generation oral and IV antibiotics to combat infectio...

DUBLIN and CHICAGO, Aug. 02, 2024 Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company dedicated to the advancement of innovative oral and intravenous antibiotics, has announced significant pr...

Iterum Therapeutics plc, a clinical-stage pharmaceutical company specializing in the development of advanced oral and IV antibiotics, has recently announced the commencement of its rights offering. This press release si...

Iterum Therapeutics plc, a leading clinical-stage pharmaceutical company specializing in the development of advanced oral and intravenous antibiotics to combat infections caused by multi-drug resistant pathogens, announ...

Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem: Bridging the Treatment Gap for uUTIsIterum Therapeutics, a leading pharmaceutical company, has recently resubmi...

Iterum Therapeutics Provides Business Update: Resubmission of NDA is On Track for First Half of Q2 24Iterum Therapeutics, a renowned pharmaceutical company specializing in the development and commercialization of innova...